Search

Objective: This study aims to evaluate the safety of a short hydration (SH) protocol during concurrent chemoradiotherapy (CCRT) with cisplatin for cervical cancer. While massive hydration is a standard for cisplatin chemotherapy to prevent renal toxicity, the safety of SH in the context of CCRT remains underexplored. Methods: We retrospectively reviewed cervical cancer patients undergoing cisplatin-based CCRT at two hospitals from January 2019 to August 2023, excluding those with poor performance status and pre-existing renal impairment. SH involved infusing up to 2 L of fluid within 5 hours on cisplatin days, while prolonged hydration (LH) exceeded this volume or this time. We compared serum creatinine levels (sCr, mg/dL) at baseline, after each cisplatin dose, and 3-6 months post-CCRT (long term) between the 2 groups. Results: Among 86 patients, 25 received SH, and 61 received LH. The SH group had a higher mean age than the LH group (49 vs. 56, p=0.047). There were no significant differences in body weight, stage, surgery ratio, and total cisplatin dose per body surface area between the 2 groups. None of the SH patients required cisplatin dose reduction or discontinuation due to nephrotoxicity, while one and 2 patients in the LH group, respectively. Mean sCr levels at baseline, the last cisplatin dose, and the long term were 0.62, 0.56, and 0.61 in SH, and 0.61, 0.66, and 0.67 in LH (p=0.72, p=0.04, and p=0.15, respectively). Conclusion: SH during CCRT for cervical cancer demonstrates no inferiority in safety compared to LH, with no significant increase in nephrotoxicity. [ABSTRACT FROM AUTHOR]